Adequacy of Disease Control by Supraomohyoid Neck Dissection in cT1/T2 Tongue Cancer.

Andrea Iandelli Filippo MarchiAn-Chieh ChenChi-Kuan YoungChun-Ta LiaoChung-Kan TsaoChung-Jan KangHung-Ming WangTung-Chieh Joseph ChangShiang-Fu Huang

Published in: Journal of personalized medicine (2022)

Treating cT1-2 N0/+ tongue cancer with SOHND is oncologically safe. ENE and MNM patients do not benefit from an mRND.

Keyphrases